GlassScriptPhysician profile
Charles V Buckmaster
NPI 1194711382
$3,716.25
in general payments reported to CMS, 2019-2025
34 companies · $421 in 2025
The $421 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $356 · 2021: $888 · 2022: $552 · 2023: $815 · 2024: $277 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.72 | 2021-2025 | Vraylar, Viberzi, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.92 | 2019-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $351.41 | 2019-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $315.92 | 2019-2025 | Rexulti, Nuedexta |
| Amgen INC. | $227.29 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Medtronic, INC. | $161.55 | 2022-2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $144.76 | 2019-2025 | Airsupra, Farxiga |
| Allergan, INC. | $134.68 | 2020 | |
| Indivior INC. | $133.15 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $126.42 | 2021-2025 | Loreev Xr |
| Pfizer INC. | $98.92 | 2019-2021 | |
| Lundbeck LLC | $76.01 | 2022-2025 | Rexulti |
| Orexo US, INC. | $68.96 | 2019-2021 | |
| Novo Nordisk INC | $64.73 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $64.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $47.68 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.02 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $43.04 | 2019 | |
| Amarin Pharma, INC. | $41.53 | 2021 | |
| Axsome Therapeutics, INC. | $40.80 | 2023-2024 | Auvelity |
| Lilly USA, LLC | $40.64 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $32.71 | 2023 | Horizant |
| Novartis Pharmaceuticals Corporation | $28.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.25 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $24.81 | 2021 | |
| Mylan Specialty L.P. | $17.08 | 2024 | Yupelri |
| Hikma Pharmaceuticals USA | $15.43 | 2024 | Kloxxado, Ryaltris |
| Biodelivery Sciences International, INC. | $15.25 | 2020 | |
| Eisai INC. | $14.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2021 | |
| Daiichi Sankyo INC. | $13.99 | 2019 | |
| Astellas Pharma US INC | $13.93 | 2025 | Veozah |
| Mdd US Operations, LLC | $12.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Buckmaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.